


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:48:23Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406870" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406870</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmjo</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="pmc-domain-id">1609</journal-id><journal-id journal-id-type="pmc-domain">bmjo</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406870</article-id><article-id pub-id-type="pmcid-ver">PMC12406870.1</article-id><article-id pub-id-type="pmcaid">12406870</article-id><article-id pub-id-type="pmcaiid">12406870</article-id><article-id pub-id-type="pmid">40897496</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2025-101029</article-id><article-id pub-id-type="publisher-id">bmjopen-2025-101029</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Global Health</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1699</subject><subject>1506</subject></subj-group></article-categories><title-group><article-title>Prevalence of viral hepatitis in sub-Saharan Africa among the general population: an umbrella review of systematic reviews and meta-analyses</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-2641-0599</contrib-id><name name-style="western"><surname>Sticher</surname><given-names initials="JS">Julia Sophie</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Csermak</surname><given-names initials="KR">Katalin R</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Otsyula</surname><given-names initials="N">Nekoye</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-4519-738X</contrib-id><name name-style="western"><surname>Turkson</surname><given-names initials="M">Moise</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1181-7265</contrib-id><name name-style="western"><surname>Aubrun</surname><given-names initials="E">Elodie</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0279-1021</contrib-id><name name-style="western"><surname>Oshagbemi</surname><given-names initials="OA">Olorunfemi A</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp"/></contrib><aff id="aff1"><label>1</label><institution content-type="department">Department of Chemistry and Applied Biosciences</institution>, <institution>ETH Zurich</institution>, <addr-line content-type="city">Z&#252;rich</addr-line>, <country>Switzerland</country></aff><aff id="aff2"><label>2</label><institution>Novartis Pharma AG</institution>, <addr-line content-type="city">Basel</addr-line>, <country>Switzerland</country></aff><aff id="aff3"><label>3</label><institution>Novartis Pharma Services</institution>, <addr-line content-type="city">Nairobi</addr-line>, <country>Kenya</country></aff></contrib-group><author-notes><fn><p>Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></fn><fn fn-type="COI-statement" id="fn4"><p>JSS and MT have nothing to declare. NO, EA and OAO are Novartis employees and own shares in the company. EA also owns shares in Sandoz. KRC was an employee of Novartis at the time of this study and manuscript development and owns shares in the company.</p></fn><corresp id="cor1">Dr Olorunfemi A Oshagbemi; <email xlink:href="femi.oshagbemi@novartis.com">femi.oshagbemi@novartis.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>9</month><year>2025</year></pub-date><volume>15</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496158</issue-id><elocation-id>e101029</elocation-id><history><date date-type="received"><day>21</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-05 01:25:50.193"><day>05</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:&#160;<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="bmjopen-15-9.pdf"/><self-uri xlink:title="pdf" xlink:href="bmjopen-15-9.pdf"/><abstract><sec><title> Abstract</title></sec><sec><title>Objectives</title><p>Hepatic impairment, especially hepatitis, is a growing public health concern in the general population globally. Viral hepatitis, a key driver of liver impairment, remains endemic in many countries across sub-Saharan Africa (SSA). We conducted an umbrella review to assess the prevalence of viral hepatitis among the general population in SSA.</p></sec><sec><title>Design</title><p>We conducted an umbrella review, using standardised methods to assess multiple systematic reviews and meta-analyses (SRMAs) on the prevalence of viral hepatitis.</p></sec><sec><title>Data sources</title><p>We systematically searched PubMed and Embase to retrieve systematic reviews published from 2013&#8211;2024.</p></sec><sec><title>Eligibility criteria for selecting studies</title><p>We retrieved systematic reviews published during 2013&#8211;2024 that examined the prevalence of viral hepatitis among the general population within SSA.</p></sec><sec><title>Data extraction and synthesis</title><p>Two independent reviewers used standardised methods to search, screen and identify included studies. We conducted an umbrella review, which was a comprehensive and systematic collation and assessment of SRMAs focused on the prevalence of viral hepatitis in SSA.</p></sec><sec><title>Results</title><p>The final analysis included 21 studies. Among these, one study focused on hepatitis A, 13 on hepatitis B, 10 on hepatitis C, 2 on hepatitis D and 1 on hepatitis E. Only one study reported the overall prevalence of hepatitis A and E in SSA as 90 200 and 46 860 per 100 000 population, respectively. Across SSA, hepatitis B exhibited a pooled prevalence ranging from 6000 to 18 900, while hepatitis C ranged from 720 to 7820 and hepatitis D from 50 to 28 990 per 100 000 population. Heterogeneity was high and ranged from I<sup>2</sup>=63.14%&#8201;to 99%.</p></sec><sec><title>Conclusion</title><p>We present an umbrella review on viral hepatitis prevalence in SSA, providing an overall view of study quality, effect sizes, heterogeneity and bias across the search field. We found that the prevalence of viral hepatitis in many SSA countries is higher than the global estimate. However, these results are mainly based on seropositivity tests; nonetheless, the findings from this study provide an overarching picture of the burden of viral hepatitis within populations in SSA.</p></sec></abstract><kwd-group><kwd>Prevalence</kwd><kwd>EPIDEMIOLOGY</kwd><kwd>Systematic Review</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004336</institution-id><institution>Novartis</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>STRENGTHS AND LIMITATIONS OF THIS STUDY</title></caption><list list-type="bullet" list-content="ul"><list-item><p>The review uniquely integrates prevalence data across multiple hepatitis viruses (A&#8211;E) and diverse sub-Saharan Africa (SSA) subregions, offering a panoramic view of the epidemiological landscape.</p></list-item><list-item><p>Data from a broad population are presented, enabling insights into viral hepatitis across SSA.</p></list-item><list-item><p>Quality appraisal allowed assessment of the reliability of the estimates.</p></list-item><list-item><p>Selection and publication biases were encountered, particularly with the lack of published research from Southern and Central Africa.</p></list-item><list-item><p>The reliance on seropositivity as a diagnostic criterion may overestimate prevalence, as it neither distinguishes active, chronic or resolved infections nor confirms liver dysfunction.</p></list-item></list></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p> Viral hepatitis represents a significant disease burden worldwide, affecting several hundred million people.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> Globally, hepatitis remains a leading cause of chronic liver disease, and sustained hepatitis C infection is associated with cirrhosis, liver cancer, hepatic failure and death.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref></p><p>Reports have shown disparities in the levels of endemicity of viral hepatitis across the world, with sub-Saharan Africa (SSA) among the high-endemic areas. Viral hepatitis is an inflammation of the liv</p><p>er due to a viral infection that can occur in an acute or chronic form. The most common agents causing viral hepatitis are hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV) and hepatitis E virus (HEV). Hepatitis A and E are typically caused by the ingestion of contaminated food or water. Hepatitis B, C and D usually occur as a result of parenteral contact with infected body fluids. Only HBV, HCV and HDV frequently cause chronic hepatitis, which can cause significant morbidity and mortality due to cirrhosis and hepatocellular carcinoma (HCC) (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure S1</xref>).<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> HCC is the third leading cause of cancer-related deaths worldwide.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> In 2019, the WHO estimated that 254&#8201;million people (as per the 2024 report) worldwide were living with chronic HBV infection and 50&#8201;million people (as per the 2024 report) with chronic HCV infection.<xref rid="R5" ref-type="bibr"><sup>5 6</sup></xref> Five percent of people who have chronic HBV infection become infected with HDV, the most severe and rapidly progressive form of chronic viral hepatitis.<xref rid="R7" ref-type="bibr"><sup>7 8</sup></xref> HDV is a defective RNA virus that requires the hepatitis B surface antigen (HBsAg) for in vivo transmission.<xref rid="R9" ref-type="bibr"><sup>9</sup></xref> Hepatitis D acquired by superinfection leads to chronic hepatitis D in 90% of cases.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref> HBV, HCV and alcohol misuse were responsible for 70% of cirrhosis cases in SSA between 1980 and 2010.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref> Cirrhosis was the 10th leading cause of death in Africa in 2017.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref></p><p>In May 2016, the WHO adopted a global strategy aimed at eliminating viral hepatitis by 90% as a public health threat by 2030. The targets to be achieved are mostly geared towards reducing the morbidity and mortality due to chronic HBV and HCV infection.<xref rid="R12" ref-type="bibr"><sup>12</sup></xref></p><p>SSA has a pronounced disease burden, but a detailed epidemiology and understanding of the disease burden are absent. A significant drawback in this regard is the scarcity of reliable and robust prevalence data from population-based studies estimating the prevalence of viral hepatitis in SSA.<xref rid="R13" ref-type="bibr"><sup>13</sup></xref></p><p>Thus, in the drive to reduce the burden of viral hepatitis in SSA, it is essential to elucidate the overall disease picture within the region. The aim of this study was to better understand the burden of viral hepatitis in SSA. Hence, we evaluated the prevalence of viral hepatitis caused by all hepatitis viruses in the general population within SSA.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>Study design and search strategy</title><p>We conducted an umbrella review, which is a comprehensive and systematic collection and assessment of multiple systematic reviews and meta-analyses (SRMAs) done on a specific research topic.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> The methods of the umbrella review are standardised and follow the principles presented by Belbasis <italic toggle="yes">et al</italic>.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> We systematically searched through Embase (via Ovid) and PubMed to identify SRMAs of observational studies reporting pooled prevalences of viral hepatitis (type A, B, C, D and E) among the general population of countries in SSA. SMRAs published between 1 January 2013 and 26 April 2024 were of interest. The search strategy used the keywords &#8220;Human Viral Hepatitis&#8221; AND &#8220;prevalence&#8221; AND &#8220;Sub-Saharan Africa&#8221; AND &#8220;systematic review&#8221; and related free terms. These keywords were concatenated using the appropriate operators to identify the publications of interest (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S1</xref>). The search was limited to studies published in the English language and research in human subjects.</p></sec><sec id="s2-2"><title>Inclusion/exclusion criteria</title><p>We included SRMAs reporting the pooled prevalence of viral hepatitis in the general population of SSA. Prevalence of viral hepatitis was based on seropositivity as a surrogate for the prevalence of liver impairment. Primary studies included in the SRMAs had to be observational, preferably cross-sectional. The general population was composed of diverse population groups, which include pregnant women, HIV patients, blood donors and high-risk groups, among others. We included studies in which the diagnosis of the hepatitis virus was based on serological assays that detect the HBsAgs or specific antibodies to HAV, HCV, HDV, or HEV. SSA was defined as Western, Eastern, Southern and Central Africa according to the United Nations geoscheme for Africa.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> We included data from Sudan in the East Africa subregion (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure S2, table S2</xref>). We excluded systematic reviews where no meta-analysis or reported pooled prevalence was reported.</p></sec><sec id="s2-3"><title>Data extraction</title><p>We screened all studies according to the titles and abstracts. If the articles met the eligibility criteria, a full-text assessment was conducted. Publications cross-referenced in articles identified by the search were reviewed to find more articles of interest. Using a predesigned data extraction form, we extracted the following data from each study: name of the primary author, publication year, country/counties, study design, number of eligible primary studies, study sample N, number of cases n, outcome definition, pooled prevalence per 100 000 population (confidence interval 95%) in the general population and subgroups, heterogeneity (I<sup>2</sup>, p value) and the score of the quality assessment. Prevalence was reported per 100 000 population, as this is the standard used by the Institute for Health Metrics and Evaluation and thus facilitates comparison. The data from the systematic reviews were then stratified into five subregions: Northern, Eastern, Central, Western and Southern SSA (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure S2</xref>). Because of potential overlaps of primary studies between systematic reviews, we did not pool the results further. Non-reported characteristics were reported as such. Own calculations were marked with a star (&#8216;*&#8217;). The plots were created with GraphPad Prism 9. We used QGIS Desktop V.3.28.3, an open-source geographic information system, to create and visualise geospatial information in the form of a geographical map.</p></sec><sec id="s2-4"><title>Methodological quality assessment</title><p>We applied the Joanna Briggs Institute (JBI) critical appraisal checklist for systematic reviews to assess the risk of bias or quality of the included SRMAs.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref> The checklist consists of 11 questions (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S3</xref>). &#8216;Yes&#8217; results in a score of 1 and &#8216;No&#8217; or &#8216;Unclear&#8217; in a score of 0.</p></sec><sec id="s2-5"><title>Patient and public involvement</title><p>Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. However, the research findings would be of interest to patient advocacy groups and public health stakeholders for research/advocacy. We acknowledge the importance of patient perspectives and plan to make our findings accessable to patient and/or public organizations as needed.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>Initially, 194 studies were retrieved from the databases and manually screened. Of all the articles assessed, 21 met the inclusion criteria for this study and were therefore included in the review. One article reported on the prevalence of hepatitis A, 1 on hepatitis E, 2 on hepatitis D, 13 on hepatitis B and 10 on hepatitis C (<xref rid="F1" ref-type="fig">figure 1</xref>). Most studies identified and included in this review were studies conducted on children and adult populations, with most studies not reporting the age range of individuals enrolled.</p><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><title>Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart for identification and selection of studies for inclusion in the review.</title></caption><graphic position="float" orientation="portrait" xlink:href="bmjopen-15-9-g001.jpg"/></fig><sec id="s3-1"><title>Epidemiology of hepatitis A</title><p>Only one study reported a pooled prevalence for HAV. The prevalence data and other indicators were extracted from a study by Hassan-Kadle <italic toggle="yes">et al</italic>.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> The total number of study participants used for HAV screening was 1564, drawn from four studies conducted in Somalia between 1984 and 1994. The random-effects model calculated a pooled anti-HAV seroprevalence (/100 000 population) of 90 200 (95% CI 77 800 to 96 000) (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S4</xref>).<xref rid="R18" ref-type="bibr"><sup>18</sup></xref></p></sec><sec id="s3-2"><title>Epidemiology of hepatitis B</title><sec id="s3-2-1"><title>General assessment</title><p>A total of 13 articles, which included 466 primary studies, assessed the HBsAg seroprevalence of 1 157 085 participants. The pooled prevalence (/100 000 population) of hepatitis B ranged from 6000 (95% CI 5000 to 6000) to 18 900 (95% CI 14 000 to 29 000) (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S5</xref>).</p></sec><sec id="s3-2-2"><title>Prevalence by sampling region</title><p>Central Africa was represented by one study that included 44 primary studies and 105 603 participants (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S5</xref>). The study was conducted in Cameroon and estimated a pooled HBV prevalence of 11 200 (95% CI 9700 to 12 800) (<xref rid="T1" ref-type="table">table 1</xref>).<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> A total of 7 studies that included 256 primary studies and 761 236 participants estimated HBV prevalence in Eastern Africa. The HBV prevalence ranged from 6000 (95% CI 5000 to 6000) to 18 900 (95% CI 14 000 to 29 000) (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S5</xref>).<xref rid="R18" ref-type="bibr">1820</xref><xref rid="R25" ref-type="bibr">25</xref> The highest HBV prevalence was found in Somalia, and the lowest in Ethiopia (<xref rid="T1" ref-type="table">table 1</xref>). Five studies represented Western Africa with a total study sample of 290 246 and 166 primary studies. The pooled HBV prevalence ranged from 8180 (95% CI 6940 to 9610) to 13 600 (95% CI 11 500 to 15 700), with the highest pooled HBV prevalence estimated in Nigeria and the lowest in Ghana (<xref rid="T1" ref-type="table">table 1</xref> and <xref rid="SP1" ref-type="supplementary-material">online supplemental table S5</xref>).<xref rid="R26" ref-type="bibr">26</xref><xref rid="R30" ref-type="bibr">30</xref> No systematic review estimated HBV prevalence in Southern Africa. Somalia had the highest prevalence in all subregions and was an outlier in Eastern Africa (<xref rid="F2" ref-type="fig">figure 2</xref>). We found a high variability within Eastern Africa (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure S3</xref>) and within countries such as Nigeria and Ghana (<xref rid="T1" ref-type="table">table 1</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><title>Characteristics of the studies included in the umbrella review on the prevalence of HBsAg in SSA</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1">Publications</th><th valign="bottom" rowspan="1" colspan="1">Country/study period</th><th valign="bottom" rowspan="1" colspan="1">Number of primary studies</th><th valign="bottom" rowspan="1" colspan="1">Study sample (N)/total number of cases (n)</th><th valign="bottom" rowspan="1" colspan="1">Outcome definition</th><th valign="bottom" rowspan="1" colspan="1">Pooled prevalence (/100 000) (95% CI)</th><th valign="bottom" rowspan="1" colspan="1">I<sup>2</sup> (p value)</th><th valign="bottom" rowspan="1" colspan="1">Quality assessment</th></tr></thead><tbody><tr><td colspan="8" align="left" valign="top" rowspan="1">Central Africa</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Bigna <italic toggle="yes">et al</italic><xref rid="R19" ref-type="bibr"><sup>19</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Cameroon/2001&#8211;2016</td><td align="left" valign="top" rowspan="1" colspan="1">44</td><td align="left" valign="top" rowspan="1" colspan="1">105 603/13 910<xref rid="T1_FN2" ref-type="table-fn">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">HBV defined according to RDT, ELISA and EIA</td><td align="left" valign="top" rowspan="1" colspan="1">11&#8201;200 (9700 to 12 800)</td><td align="left" valign="top" rowspan="1" colspan="1">97.9% (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Eastern Africa</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Badawi <italic toggle="yes">et al</italic><xref rid="R20" ref-type="bibr"><sup>20</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Sudan/2007&#8211;2016</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">5848/NR</td><td align="left" valign="top" rowspan="1" colspan="1">HBV defined by the presence of HBV antibodies or HBsAg</td><td align="left" valign="top" rowspan="1" colspan="1">9100 (7110 to 11 040)</td><td align="left" valign="top" rowspan="1" colspan="1">91% (p&lt;0.00001)</td><td align="left" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Belyhun <italic toggle="yes">et al</italic><xref rid="R21" ref-type="bibr"><sup>21</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Ethiopia/1983&#8211;2015</td><td align="left" valign="top" rowspan="1" colspan="1">62</td><td align="left" valign="top" rowspan="1" colspan="1">NR/NR</td><td align="left" valign="top" rowspan="1" colspan="1">HBsAg with immunoassay-based kits and four studies used PCR</td><td align="left" valign="top" rowspan="1" colspan="1">7400 (6500 to 8400)</td><td align="left" valign="top" rowspan="1" colspan="1">91.9% (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Hassan-Kadle <italic toggle="yes">et al</italic><xref rid="R18" ref-type="bibr"><sup>18</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Somalia/1984&#8211;2014</td><td align="left" valign="top" rowspan="1" colspan="1">23</td><td align="left" valign="top" rowspan="1" colspan="1">8756/1445<xref rid="T1_FN2" ref-type="table-fn">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">HBsAg</td><td align="left" valign="top" rowspan="1" colspan="1">18&#8201;900 (14 000 to 29 000)</td><td align="left" valign="top" rowspan="1" colspan="1">97.6% (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Kafeero <italic toggle="yes">et al</italic><xref rid="R22" ref-type="bibr"><sup>22</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Tanzania, Uganda, Rwanda, Kenya, Burundi and South Sudan/2005&#8211;2020</td><td align="left" valign="top" rowspan="1" colspan="1">37</td><td align="left" valign="top" rowspan="1" colspan="1">525 955/22 156</td><td align="left" valign="top" rowspan="1" colspan="1">HBV defined according to testing for HBsAg with ELISA, RDT, EIA and others</td><td align="left" valign="top" rowspan="1" colspan="1">6025 (5414 to 6667)</td><td align="left" valign="top" rowspan="1" colspan="1">97.55% (p&lt;0.0001)</td><td align="left" valign="top" rowspan="1" colspan="1">11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Makokha <italic toggle="yes">et al</italic><xref rid="R23" ref-type="bibr"><sup>23</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Kenya/1990&#8211;2021</td><td align="left" valign="top" rowspan="1" colspan="1">50</td><td align="left" valign="top" rowspan="1" colspan="1">108 448/NR</td><td align="left" valign="top" rowspan="1" colspan="1">HBsAg</td><td align="left" valign="top" rowspan="1" colspan="1">7810 (5800 to 10 100)</td><td align="left" valign="top" rowspan="1" colspan="1">99% (p&lt;0.0001)</td><td align="left" valign="top" rowspan="1" colspan="1">11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Stockdale <italic toggle="yes">et al</italic><xref rid="R24" ref-type="bibr"><sup>24</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Malawi/1990&#8211;2018</td><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">6104<xref rid="T1_FN2" ref-type="table-fn">*</xref>/479<xref rid="T1_FN2" ref-type="table-fn">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">HBsAg</td><td align="left" valign="top" rowspan="1" colspan="1">8100 (6100 to 10 300)</td><td align="left" valign="top" rowspan="1" colspan="1">86.16% (p&lt;0.0001)</td><td align="left" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Yazie and Tebeje<xref rid="R25" ref-type="bibr"><sup>25</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Ethiopia/2010&#8211;2019</td><td align="left" valign="top" rowspan="1" colspan="1">60</td><td align="left" valign="top" rowspan="1" colspan="1">106 125/1484<xref rid="T1_FN2" ref-type="table-fn">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">HBsAg with ELISA, RDT, PCR and IA</td><td align="left" valign="top" rowspan="1" colspan="1">6000 (5000 to 6000)</td><td align="left" valign="top" rowspan="1" colspan="1">97.77% (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">11</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Western Africa</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Abesig <italic toggle="yes">et al</italic><xref rid="R26" ref-type="bibr"><sup>26</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Ghana/2015&#8211;2019</td><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="left" valign="top" rowspan="1" colspan="1">29 061/NR</td><td align="left" valign="top" rowspan="1" colspan="1">HBsAg with ELISA, RDT and PCR</td><td align="left" valign="top" rowspan="1" colspan="1">8180 (6940 to 9610)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Ajuwon <italic toggle="yes">et al</italic><xref rid="R27" ref-type="bibr"><sup>27</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Nigeria/2010&#8211;2019</td><td align="left" valign="top" rowspan="1" colspan="1">47</td><td align="left" valign="top" rowspan="1" colspan="1">21 702/NR</td><td align="left" valign="top" rowspan="1" colspan="1">HBsAg with ELISA, RDT, PCR, EIA and ICT</td><td align="left" valign="top" rowspan="1" colspan="1">9500 (8100 to 11 000)</td><td align="left" valign="top" rowspan="1" colspan="1">91.2% (p&lt;0.01)</td><td align="left" valign="top" rowspan="1" colspan="1">11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Lingani <italic toggle="yes">et al</italic><xref rid="R28" ref-type="bibr"><sup>28</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Burkina Faso/1996&#8211;2017</td><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">99 672/NR</td><td align="left" valign="top" rowspan="1" colspan="1">HBsAg</td><td align="left" valign="top" rowspan="1" colspan="1">11 210 (11 010 to 11 410)</td><td align="left" valign="top" rowspan="1" colspan="1">94% (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Musa <italic toggle="yes">et al</italic><xref rid="R29" ref-type="bibr"><sup>29</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Nigeria/2000&#8211;2013</td><td align="left" valign="top" rowspan="1" colspan="1">46</td><td align="left" valign="top" rowspan="1" colspan="1">34 376/NR</td><td align="left" valign="top" rowspan="1" colspan="1">HBV defined according to ELISA, ICT or DNA PCR</td><td align="left" valign="top" rowspan="1" colspan="1">13 600 (11 500 to 15 700)</td><td align="left" valign="top" rowspan="1" colspan="1">97.8% (p=0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Ofori-Asenso and Agyeman<xref rid="R30" ref-type="bibr"><sup>30</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Ghana/1995&#8211;2015</td><td align="left" valign="top" rowspan="1" colspan="1">30</td><td align="left" valign="top" rowspan="1" colspan="1">105 435/NR</td><td align="left" valign="top" rowspan="1" colspan="1">HBsAg</td><td align="left" valign="top" rowspan="1" colspan="1">12 300 (11 300 to 13 400)</td><td align="left" valign="top" rowspan="1" colspan="1">94.6% (p&lt;0.0001)</td><td align="left" valign="top" rowspan="1" colspan="1">10</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN3" fn-type="other"><p>N, population sample size; n, number of cases.</p></fn><fn id="T1_FN2" fn-type="other"><label>*</label><p>Calculation derived from data in the article.</p></fn><fn id="T1_FN1" fn-type="abbr"><p>EIA, enzyme immunoassay; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; IA, immunoassay; ICT, immunochromatography; NR, not reported; RDT, rapid diagnostic test; SSA, sub-Saharan Africa.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><title>Geographic map of the African continent visualising the distribution of HBsAg seroprevalence estimated in the included studies. In the case of multiple studies reporting pooled HBV prevalence for the same country, data from the more recent work were included in the map. Created with QGIS Desktop V.3.28.3. HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus,</title></caption><graphic position="float" orientation="portrait" xlink:href="bmjopen-15-9-g002.jpg"/></fig></sec></sec><sec id="s3-3"><title>Epidemiology of hepatitis C</title><sec id="s3-3-1"><title>General assessment</title><p>A total of 18 studies included 433 primary studies that assessed the anti-HCV seroprevalence among 829 383 participants. The pooled prevalence of hepatitis C per 100 000 population ranged from 720 (95% CI 330 to 1540) to 7820 (95% CI 5290 to 11 430) (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S6</xref>). Most studies reported the estimated prevalence for a subregion and not for a specific country (<xref rid="T2" ref-type="table">table 2</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><title>Characteristics of the studies included in the umbrella review on the prevalence of anti-HCV in SSA</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1">Publications</th><th valign="bottom" rowspan="1" colspan="1">Country/study period</th><th valign="bottom" rowspan="1" colspan="1">Number of primary studies</th><th valign="bottom" rowspan="1" colspan="1">Study sample (N)/total number of cases (n)</th><th valign="bottom" rowspan="1" colspan="1">Outcome definition</th><th valign="bottom" rowspan="1" colspan="1">Pooled prevalence (/100 000) (95%&#8201;CI)</th><th valign="bottom" rowspan="1" colspan="1">I<sup>2</sup> (p value)</th><th valign="bottom" rowspan="1" colspan="1">Quality assessment</th></tr></thead><tbody><tr><td colspan="8" align="left" valign="top" rowspan="1">Central Africa</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Bigna <italic toggle="yes">et al</italic> 2017<xref rid="R31" ref-type="bibr"><sup>31</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Cameroon/2001&#8211;2016</td><td align="left" valign="top" rowspan="1" colspan="1">31</td><td align="left" valign="top" rowspan="1" colspan="1">36 407/1541</td><td align="left" valign="top" rowspan="1" colspan="1">Anti-HCV</td><td align="left" valign="top" rowspan="1" colspan="1">6500 (4500 to 8800)</td><td align="left" valign="top" rowspan="1" colspan="1">98.3% (p=0.00)</td><td align="left" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Hanafiah <italic toggle="yes">et al</italic><xref rid="R32" ref-type="bibr"><sup>32</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Angola, Central Africa, Congo Democratic, Congo, Gabon, Equatorial Guinea/1980&#8211;2007</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR/NR</td><td align="left" valign="top" rowspan="1" colspan="1">Anti-HCV</td><td align="left" valign="top" rowspan="1" colspan="1">2300 (1600 to 3100)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Mora <italic toggle="yes">et al</italic><xref rid="R33" ref-type="bibr"><sup>33</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Central Africa (defined by WHO)/2000&#8211;2013</td><td align="left" valign="top" rowspan="1" colspan="1">32</td><td align="left" valign="top" rowspan="1" colspan="1">NR/NR</td><td align="left" valign="top" rowspan="1" colspan="1">HCV defined according to highest generation diagnostic assay used (ie, screening, second, third or fourth generation assay)</td><td align="left" valign="top" rowspan="1" colspan="1">7820 (5290 to 11 430)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Muzembo <italic toggle="yes">et al</italic><xref rid="R34" ref-type="bibr"><sup>34</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Democratic Republic of the Congo/1991&#8211;2015</td><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="left" valign="top" rowspan="1" colspan="1">13 799/NR</td><td align="left" valign="top" rowspan="1" colspan="1">Anti-HCV, by ELISA, rapid test, immunochromatographic rapid test, EIA, PCR</td><td align="left" valign="top" rowspan="1" colspan="1">2900 (1500 to 4300)</td><td align="left" valign="top" rowspan="1" colspan="1">95.6% (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Rao <italic toggle="yes">et al</italic><xref rid="R35" ref-type="bibr"><sup>35</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Central Africa/2002&#8211;2014</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR/NR</td><td align="left" valign="top" rowspan="1" colspan="1">HCV defined according to non-confirmatory and confirmatory assays</td><td align="left" valign="top" rowspan="1" colspan="1">6760 (5980 to 7550)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Eastern Africa</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Badawi <italic toggle="yes">et al</italic><xref rid="R20" ref-type="bibr"><sup>20</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Sudan/2007&#8211;2016</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">8643/NR</td><td align="left" valign="top" rowspan="1" colspan="1">Anti-HCV</td><td align="left" valign="top" rowspan="1" colspan="1">2500 (1420 to 3530)</td><td align="left" valign="top" rowspan="1" colspan="1">93% (p&lt;0.00001)</td><td align="left" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Belyhun <italic toggle="yes">et al</italic><xref rid="R21" ref-type="bibr"><sup>21</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Ethiopia/1990&#8211;2015</td><td align="left" valign="top" rowspan="1" colspan="1">32</td><td align="left" valign="top" rowspan="1" colspan="1">37 520/1133</td><td align="left" valign="top" rowspan="1" colspan="1">Anti-HCV</td><td align="left" valign="top" rowspan="1" colspan="1">3100 (2200 to 4400)</td><td align="left" valign="top" rowspan="1" colspan="1">91.9% (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Chaabna <italic toggle="yes">et al</italic><xref rid="R36" ref-type="bibr"><sup>36</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Somalia; Sudan/Somalia: 1987&#8211;1990; Sudan: 2001&#8211;2014</td><td align="left" valign="top" rowspan="1" colspan="1">Somalia: 17; Sudan: 39</td><td align="left" valign="top" rowspan="1" colspan="1">Somalia: 14 081; Sudan: 1856/Somalia: 78; Sudan: 21</td><td align="left" valign="top" rowspan="1" colspan="1">Anti-HCV</td><td align="left" valign="top" rowspan="1" colspan="1">Somalia: 900 (300 to 1900); Sudan: 1000 (300 to 1900)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Deress <italic toggle="yes">et al</italic><xref rid="R37" ref-type="bibr"><sup>37</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Ethiopia/2010&#8211;2020</td><td align="left" valign="top" rowspan="1" colspan="1">56</td><td align="left" valign="top" rowspan="1" colspan="1">710 820/4115</td><td align="left" valign="top" rowspan="1" colspan="1">Anti-HCV with ELISA or RDT</td><td align="left" valign="top" rowspan="1" colspan="1">2000 (2000 to 3000)</td><td align="left" valign="top" rowspan="1" colspan="1">97.79% (p=0.00)</td><td align="left" valign="top" rowspan="1" colspan="1">11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Hanafiah <italic toggle="yes">et al</italic><xref rid="R32" ref-type="bibr"><sup>32</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Ethiopia PDR, Kenya, Madagascar, Mozambique, Malawi, Mayotte, Rwanda, Sudan, Somalia, Tanzania, Uganda, Zambia/1980&#8211;2007</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR/NR</td><td align="left" valign="top" rowspan="1" colspan="1">Anti-HCV</td><td align="left" valign="top" rowspan="1" colspan="1">2000 (1600 to 2400)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Hassan-Kadle<xref rid="R18" ref-type="bibr"><sup>18</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Somalia/1992&#8211;2016</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">6257/382<xref rid="T2_FN2" ref-type="table-fn">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Anti-HCV</td><td align="left" valign="top" rowspan="1" colspan="1">4840 (3020 to 7670)</td><td align="left" valign="top" rowspan="1" colspan="1">93.5% (p&lt;0.0001)</td><td align="left" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Mora <italic toggle="yes">et al</italic><xref rid="R33" ref-type="bibr"><sup>33</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Eastern Africa defined by WHO/2000&#8211;2013</td><td align="left" valign="top" rowspan="1" colspan="1">67</td><td align="left" valign="top" rowspan="1" colspan="1">NR/NR</td><td align="left" valign="top" rowspan="1" colspan="1">HCV defined according to highest generation diagnostic assay used (ie, screening, second, third or fourth generation assay)</td><td align="left" valign="top" rowspan="1" colspan="1">3000 (2230 to 4020)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Southeastern Africa</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Rao <italic toggle="yes">et al</italic>
<xref rid="R35" ref-type="bibr"><sup>35</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Southeastern Africa/2002&#8211;2014</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR/NR</td><td align="left" valign="top" rowspan="1" colspan="1">HCV defined according to non-confirmatory and confirmatory assays</td><td align="left" valign="top" rowspan="1" colspan="1">910 (800 to 1020)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Western Africa</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Hanafiah <italic toggle="yes">et al</italic><xref rid="R32" ref-type="bibr"><sup>32</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Benin, Burkina Faso, C&#244;te d&#8217;Ivoire, Cameroon, Cape Verde, Ghana, Guinea, The Gambia, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Saint Helena, Sierra Leone, S&#227;o Tom&#233; and Pr&#237;ncipe, Chad, Togo/1980&#8211;2007</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR/NR</td><td align="left" valign="top" rowspan="1" colspan="1">Anti-HCV</td><td align="left" valign="top" rowspan="1" colspan="1">2800 (2400 to 3300)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Mora <italic toggle="yes">et al</italic><xref rid="R33" ref-type="bibr"><sup>33</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Western Africa defined by WHO/2000&#8211;2013</td><td align="left" valign="top" rowspan="1" colspan="1">107</td><td align="left" valign="top" rowspan="1" colspan="1">NR/NR</td><td align="left" valign="top" rowspan="1" colspan="1">HCV defined according to highest generation diagnostic assay used (ie, screening, second, third or fourth generation assay)</td><td align="left" valign="top" rowspan="1" colspan="1">4140 (3290 to 5200)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Rao <italic toggle="yes">et al</italic><xref rid="R35" ref-type="bibr"><sup>35</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Western Africa/2002&#8211;2014</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR/NR</td><td align="left" valign="top" rowspan="1" colspan="1">HCV defined according to non-confirmatory and confirmatory assays</td><td align="left" valign="top" rowspan="1" colspan="1">4340 (3990 to 4700)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Southern Africa</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Hanafiah <italic toggle="yes">et al</italic><xref rid="R32" ref-type="bibr"><sup>32</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Botswana, Lesotho, Namibia, Swaziland, South Africa, Zimbabwe/1980&#8211;2007</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR/NR</td><td align="left" valign="top" rowspan="1" colspan="1">Anti-HCV</td><td align="left" valign="top" rowspan="1" colspan="1">2100 (1700 to 2500)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Mora <italic toggle="yes">et al</italic><xref rid="R33" ref-type="bibr"><sup>33</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Southern Africa defined by WHO/2000&#8211;2013</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">NR/NR</td><td align="left" valign="top" rowspan="1" colspan="1">HCV defined according to highest generation diagnostic assay used (ie, screening, second, third or fourth generation assay)</td><td align="left" valign="top" rowspan="1" colspan="1">720 (330 to 1540)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">6</td></tr></tbody></table><table-wrap-foot><fn id="T2_FN3" fn-type="other"><p>N, population sample size; n, number of cases.</p></fn><fn id="T2_FN2" fn-type="other"><label>*</label><p>Calculation derived from data in the article.</p></fn><fn id="T2_FN1" fn-type="abbr"><p>Anti-HCV, anti-hepatitis C virus antibody; EIA, enzyme immunoassay; HCV, hepatitis C virus; NR, not reported; Ethiopia PDR, People&#8217;s Democratic Republic of Ethiopia; RDT, rapid diagnostic test; SSA, sub-Saharan Africa.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-3-2"><title>Prevalence by sampling region</title><p>Five articles comprising 79 primary studies and 50 206 participants were conducted in Central Africa. Anti-HCV prevalence ranged from 2900 (95% CI 1500 to 4300) to 7820 (95% CI 5290 to 11 430) (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S6</xref>).<xref rid="R31" ref-type="bibr">31</xref><xref rid="R35" ref-type="bibr">35</xref> Seven studies estimated anti-HCV prevalence in Eastern Africa. The studies included 232 primary studies and 779 177 participants (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S6</xref>). Pooled anti-HCV prevalence ranged from 900 (95% CI 300 to 1900) to 4840 (95% CI 3020 to 7670), with the highest and lowest prevalence both estimated in Somalia (<xref rid="T2" ref-type="table">table 2</xref>).<xref rid="R18" ref-type="bibr"><sup>18 20 21 32 33 36 37</sup></xref> Three studies represented Western Africa and included 107 primary studies. The pooled anti-HCV prevalence ranged from 2800 (95% CI 2400 to 3300) to 4340 (95% CI 3990 to 4700) (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S6</xref>).<xref rid="R32" ref-type="bibr"><sup>32 33 35</sup></xref> Rao <italic toggle="yes">et al</italic> estimated a pooled anti-HCV prevalence of 910 (95% CI 800 to 1020) in Southeastern Africa. Two studies estimated a pooled anti-HCV prevalence of 720 (95% CI 330 to 1540) and 2100 (95% CI 1700 to 2500) in Southern Africa (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S6</xref>).<xref rid="R32" ref-type="bibr"><sup>32 33</sup></xref> Three studies did not report the number of included primary studies and study samples per subregion (<xref rid="T2" ref-type="table">table 2</xref>).<xref rid="R32" ref-type="bibr"><sup>32 33 35</sup></xref> The three highest estimated anti-HCV prevalence rates came from Central Africa. We found a high variability not only between subregions but also within regions, especially within Central and Eastern Africa (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure S4</xref>).</p></sec></sec><sec id="s3-4"><title>Prevalence of hepatitis D</title><sec id="s3-4-1"><title>General assessment</title><p>A total of two studies included 31 primary studies that assessed the anti-HDV seroprevalence rate of 5716 participants. The pooled prevalence (/100 000 population) of hepatitis D ranged from 50 (95% CI 0 to 1780) to 28 990 (95% CI 16 380 to 45 960) (<xref rid="T3" ref-type="table">table 3</xref>).<xref rid="R18" ref-type="bibr"><sup>18 38</sup></xref></p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><title>Characteristics of the studies included in the umbrella review on the prevalence of anti-HDV in SSA</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1">Publications</th><th valign="bottom" rowspan="1" colspan="1">Country/study period</th><th valign="bottom" rowspan="1" colspan="1">Number of primary studies</th><th valign="bottom" rowspan="1" colspan="1">Study sample (N)/total number of cases (n)</th><th valign="bottom" rowspan="1" colspan="1">Outcome definition</th><th valign="bottom" rowspan="1" colspan="1">Pooled prevalence (/100 000) (95%&#8201;CI)</th><th valign="bottom" rowspan="1" colspan="1">I<sup>2</sup> (p value)</th><th valign="bottom" rowspan="1" colspan="1">Quality assessment</th></tr></thead><tbody><tr><td colspan="8" align="left" valign="top" rowspan="1">Central Africa</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Stockdale <italic toggle="yes">et al</italic> 2017<xref rid="R38" ref-type="bibr"><sup>38</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Cameroon, Gabon/1995&#8211;2016</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">2235/385</td><td align="left" valign="top" rowspan="1" colspan="1">Anti-HDV</td><td align="left" valign="top" rowspan="1" colspan="1">25 640 (12 090 to 42 000)</td><td align="left" valign="top" rowspan="1" colspan="1">97.04% (p=0.012)</td><td align="left" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Eastern Africa</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Hassan-Kadle <italic toggle="yes">et al</italic> 2018<xref rid="R18" ref-type="bibr"><sup>18</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Somalia/1977&#8211;2016</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">375/NR</td><td align="left" valign="top" rowspan="1" colspan="1">Anti-HDV</td><td align="left" valign="top" rowspan="1" colspan="1">28 990 (16 380 to 45 960)</td><td align="left" valign="top" rowspan="1" colspan="1">84.9% (p&lt;0.0001)</td><td align="left" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Southeastern Africa</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Stockdale <italic toggle="yes">et al</italic> 2017<xref rid="R38" ref-type="bibr"><sup>38</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Botswana, Mozambique, South Africa, Tanzania, Malawi/1995&#8211;2016</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">645/13</td><td align="left" valign="top" rowspan="1" colspan="1">Anti-HDV</td><td align="left" valign="top" rowspan="1" colspan="1">50 (0 to 1780)</td><td align="left" valign="top" rowspan="1" colspan="1">63.14% (p=0.01)</td><td align="left" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td colspan="8" align="left" valign="top" rowspan="1">Western Africa</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Stockdale <italic toggle="yes">et al</italic> 2017<xref rid="R38" ref-type="bibr"><sup>38</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">Benin, Burkina Faso, The Gambia, Ghana, Guinea-Bissau, Mauritania, Nigeria, Senegal/1995&#8211;2016</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">2461/208</td><td align="left" valign="top" rowspan="1" colspan="1">Anti-HDV</td><td align="left" valign="top" rowspan="1" colspan="1">7330 (3550 to 12 200)</td><td align="left" valign="top" rowspan="1" colspan="1">93.12% (p&lt;0.0001)</td><td align="left" valign="top" rowspan="1" colspan="1">9</td></tr></tbody></table><table-wrap-foot><fn id="T3_FN2" fn-type="other"><p>N, population sample size; n, number of cases.</p></fn><fn id="T3_FN1" fn-type="abbr"><p>Anti-HDV, anti-hepatitis D virus antibody; NR, not reported; SSA, sub-Saharan Africa.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-4-2"><title>Prevalence by sampling region</title><p>Stockdale <italic toggle="yes">et al</italic> estimated the anti-HDV seroprevalence in Central, Western, and Southeastern Africa. The pooled anti-HDV prevalence was 25 640 (95% CI 12 090 to 42 000) in Central Africa, 7300 (95% CI 3550 to 12 200) in Western Africa and 50 (95% CI 0 to 1780) in Central Africa. Hassan-Kadle <italic toggle="yes">et al</italic> estimated an anti-HDV prevalence of 28 990 (95% CI 16 380 to 45 960) in Eastern Africa (<xref rid="T3" ref-type="table">table 3</xref>).<xref rid="R18" ref-type="bibr"><sup>18</sup></xref></p></sec></sec><sec id="s3-5"><title>Prevalence of hepatitis E</title><p>The HEV prevalence data per 100 000 population and other indicators were extracted from a study by Hassan-Kadle <italic toggle="yes">et al</italic>.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> The total number of study participants used for HEV screening was 287, drawn from three studies conducted in Somalia between 1977 and 2016. The random-effects model estimated a pooled anti-HEV prevalence of 46 860 (95% CI 5310 to 93 280) (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S7</xref>).</p></sec><sec id="s3-6"><title>Quality assessment</title><p>We assessed the risk of bias or quality of all included studies with the JBI critical appraisal of included systematic reviews. The score of the JBI critical appraisal checklist (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S3</xref>) ranged from 6 to 11 points. We reported an average score of 9.4 out of 11 points. Overall, 29% (6/21) of the studies achieved the highest score. In 43% of the studies, it was stated clearly that critical appraisal was conducted by two or more reviewers independently, and 71% of studies addressed the likelihood of publication bias (<xref rid="F3" ref-type="fig">figure 3</xref>).</p><fig position="float" id="F3" fig-type="figure" orientation="portrait"><label>Figure 3</label><caption><title>Joanna Briggs Institute critical appraisal of included systematic reviews.</title></caption><graphic position="float" orientation="portrait" xlink:href="bmjopen-15-9-g003.jpg"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Viral hepatitis is a major public health concern, especially in developing countries.<xref rid="R39" ref-type="bibr"><sup>39</sup></xref> To our knowledge, this review is the first umbrella review that has attempted to thoroughly summarise evidence on the different types of viral hepatitis in SSA. This umbrella review aimed to understand the burden of viral hepatitis in SSA by assessing the prevalence of the disease in SSA. Furthermore, results from this study have the potential to inform healthcare professionals and policymakers in the development of national strategies for the prevention and control of viral hepatitis. The findings of this review show a variable burden of viral hepatitis in SSA, which is mostly driven by the population enrolled, duration of study and assessment of the endpoints of interest.</p><sec id="s4-1"><title>Epidemiology of hepatitis B</title><p>Western and Central Africa (Burkina Faso, Cameroon, Ghana, and Nigeria) had high HBV prevalence according to the WHO criteria for HBV endemicity (&gt;8%, high; 2&#8211;7%, moderate and &lt;2%, low). We found the highest pooled HBV prevalence in Somalia, possibly because nearly half of the study populations included by Hassan-Kadle <italic toggle="yes">et al</italic> were considered as high-risk groups and because Somalia was considered to have no national strategy for viral hepatitis surveillance, prevention and control.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> However, more recently, the national immunisation policy and the Expanded Programme on Immunisation by the Somalian government recommend that all children under 2 years of age should receive vaccinations, including for hepatitis B.<xref rid="R40" ref-type="bibr"><sup>40</sup></xref> The global prevalence of 3.61% was exceeded in all SSA regions.<xref rid="R41" ref-type="bibr"><sup>41</sup></xref> This emphasises that the hepatitis B burden is still high in SSA. Most SRMAs included primary studies that reported seroprevalence in blood donors, pregnant women and HIV-infected persons. Pregnant women infected with HBV may transmit their disease to their babies at birth, and blood donors to their recipients.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> Individuals with immunodeficiency might be particularly susceptible to viral hepatitis.<xref rid="R42" ref-type="bibr"><sup>42</sup></xref> However, they are not necessarily representative of the general population. The risk of chronic infection after exposure to HBV is almost 90% when infection occurs during the perinatal period.<xref rid="R43" ref-type="bibr"><sup>43</sup></xref> Although our results showed lower prevalence in children, Ajuwon <italic toggle="yes">et al</italic> and Musa <italic toggle="yes">et al</italic> reported high endemicity (11 400 per 100 000 and 11 500 per 100 000, respectively) in Nigerian children.<xref rid="R27" ref-type="bibr"><sup>27 29</sup></xref> Vaccination against hepatitis B was introduced in Nigeria in 2004, but coverage is lower than that in many sub-Saharan countries because immunisation programmes in Nigeria do not receive adequate attention and funding from the government.<xref rid="R27" ref-type="bibr"><sup>27 44 45</sup></xref> Although the general trend of hepatitis B prevalence is downward, the WHO&#8217;s goal of eliminating HBV in SSA by 2030 seems unattainable unless health system development is aimed toward universal coverage. In 2021, the WHO established the 2021&#8211;2030 Framework for an Integrated Multisectoral Response to tuberculosis, HIV, sexually transmitted infections, and hepatitis in the African region. The aim is to support milestones that include the introduction of the Hepatitis B birth dose vaccine in 35 Member States, diagnosis of at least 30% of those with chronic hepatitis infections and the achievement of 30% of people with hepatitis B and C on treatment. Progress in prevention, diagnosis, and treatment was impeded between 2019 and 2021 due to the insufficient implementation of hepatitis interventions in countries.<xref rid="R46" ref-type="bibr"><sup>46</sup></xref></p></sec><sec id="s4-2"><title>Epidemiology of hepatitis C</title><p>Chaabna <italic toggle="yes">et al</italic><xref rid="R36" ref-type="bibr"><sup>36</sup></xref>, Mora <italic toggle="yes">et al</italic><xref rid="R33" ref-type="bibr"><sup>33</sup></xref> and Rao <italic toggle="yes">et al</italic><xref rid="R35" ref-type="bibr"><sup>35</sup></xref> reported anti-HCV prevalence below 1% in southern, southeast Africa, and particularly in Somalia, Sudan, and Yemen, which is less than the global prevalence of 1.8%.<xref rid="R47" ref-type="bibr"><sup>47</sup></xref> However, most included individual observational studies estimated the anti-HCV prevalence above 2%. The findings of <italic toggle="yes">Rao et al</italic>, showing that the highest anti-HCV prevalence occurs in Central Africa, are consistent with our findings.<xref rid="R35" ref-type="bibr"><sup>35</sup></xref> Three reviews reported an especially high anti-HCV prevalence, which differs from two others conducted in Central Africa in that they do not include data before the year 2000 (<xref rid="T2" ref-type="table">table 2</xref>). HCV was identified in 1989 as a major cause of parenterally transmitted non-A non-B hepatitis, and one can assume that prevalence, especially of chronic hepatitis, continuously increased before effective treatment was available.<xref rid="R48" ref-type="bibr"><sup>48</sup></xref> This might explain the positive prevalence trend estimated by Belyhun <italic toggle="yes">et al</italic><xref rid="R21" ref-type="bibr"><sup>21</sup></xref> and Deress <italic toggle="yes">et al</italic><xref rid="R37" ref-type="bibr"><sup>37</sup></xref> even after the year 2010 (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure S5</xref>). Until recently, HCV treatment was based on interferon, which has many side effects.<xref rid="R49" ref-type="bibr"><sup>49</sup></xref> The advent of direct-acting antiviral (DAA) tablets has dramatically changed HCV treatment. Nowadays, DDAs can cure more than 95% of HCV-infected persons; however, access to diagnosis and treatment is low.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> We need more recent data on the prevalence of HCV infection since all studies, but Deress <italic toggle="yes">et al</italic><xref rid="R37" ref-type="bibr"><sup>37</sup></xref> were published before 2020. Furthermore, access to screening for HCV and treatment should be urgently scaled up within SSA.</p></sec><sec id="s4-3"><title>Epidemiology of hepatitis A</title><p>Hassan-Kadle <italic toggle="yes">et al</italic><xref rid="R18" ref-type="bibr"><sup>18</sup></xref> estimated that in Somalia between 1984 and 1994, among the studies presented in Somalia, more than 90% of children had the HAV antibody by the age of 4 years. Three studies in Ethiopia in the 1980s found that more than 90% of children were immune by the age of 10 years.<xref rid="R18" ref-type="bibr">1850</xref><xref rid="R52" ref-type="bibr">52</xref> In many parts of the world, vaccine development has led to a decrease in HAV prevalence, but it is important to consider that in some cases, the reduced risk of infection has significantly increased the average age at infection, which is associated with a more severe form of disease.<xref rid="R53" ref-type="bibr"><sup>53 54</sup></xref> HAV infection is associated with low socioeconomic status and poor sanitary conditions; therefore, it might still be more prevalent in developing countries than the global average.<xref rid="R53" ref-type="bibr"><sup>53</sup></xref> However, it must be highlighted that there are few hepatitis A registries in SSA and many cases are asymptomatic, and so the reporting and capture of hepatitis A cases is known to be incomplete.<xref rid="R55" ref-type="bibr"><sup>55</sup></xref> In addition, children under 1 year of age in regions of high endemicity often have maternal antibodies.<xref rid="R56" ref-type="bibr"><sup>56</sup></xref> As with most vaccines, ageing of an individual reduces seroconversion rates and generally accelerates waning of antibody titres, with studies showing that the first dose of HAV vaccine induced adequate antibody responses in 100% of young adults, but in only 65% of individuals aged &#8805;50 years.<xref rid="R57" ref-type="bibr"><sup>57</sup></xref></p></sec><sec id="s4-4"><title>Epidemiology of hepatitis D</title><p>Since HDV requires HBsAg for its replication, we expected the highest anti-HDV prevalence in Western Africa, but our findings suggest that the anti-HDV seroprevalence is highest in Somalia and Central Africa. However, one must be careful when comparing HbsAg to anti-HDV seropositivity, as the latter only indicates exposure to the virus and not necessarily ongoing infection. The current global prevalence remains undetermined, but three meta-analyses estimated the number of HDV-infected persons worldwide to range from 12 to 72 million.<xref rid="R58" ref-type="bibr"><sup>58</sup></xref> Clinical studies have shown that chronic hepatitis D is the most severe and progressive form of viral hepatitis in humans.<xref rid="R59" ref-type="bibr"><sup>59</sup></xref> Since our findings demonstrate a high anti-HDV prevalence in Central and Eastern Africa, more research on the current epidemiology and valid therapies to cure the disease is urgently needed.</p></sec><sec id="s4-5"><title>Epidemiology of hepatitis E</title><p>Only one systematic review, conducted in Somalia, reported the anti-HEV seroprevalence in SSA. The pooled anti-HEV prevalence (/100 000 population) was 46 860 (95% CI 5310 to 93 280).<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> Li <italic toggle="yes">et al</italic> reported a hepatitis E seroprevalence of 21.76% on the African continent with the highest prevalence of 74.76% in South Sudan. More data are required to understand the prevalence of HEV infection, optimal treatment and prevention.<xref rid="R60" ref-type="bibr"><sup>60</sup></xref></p></sec><sec id="s4-6"><title>Quality assessment</title><p>The JBI critical appraisal checklist was employed to assess the risk of bias and quality of the included studies. From the assessment, an average of 9.4 out of 11 points was obtained. This suggests that the average quality of the included studies was high. Over half of the studies received a score of 10 or more, which can be considered high quality. We decided not to use a defined scale since the definitions would be arbitrary, even though it might be useful to exclude studies that the authors consider as low quality. This, however, was not the goal in this review.</p></sec><sec id="s4-7"><title>Study strengths and limitations</title><p>This is the first umbrella review to focus on viral hepatitis in SSA. This study offers a comprehensive overview of study quality, effect sizes, uncertainty, heterogeneity and biases across a broad research field. This design is particularly valuable when multiple up-to-date SRMAs have already been published on a topic, as it helps consolidate existing evidence, conserves research resources and identifies gaps within the field. This initial umbrella review presents the national pooled prevalence of viral hepatitis across several SSA countries and subregions. It also captures a wide range of risk factors and transmission routes, reflecting the diversity of the populations and regions studied. Importantly, the review identifies research gaps in specific subregions and countries, particularly for hepatitis A, D and E. Overall, it provides a strong synthesis of study quality, effect sizes, heterogeneity and bias across a broad evidence base.</p><p>Despite these strengths, the review has several limitations. There is a lack of research from Southern and Central Africa, and data from some countries are sparse or entirely missing. Additionally, few studies focus on hepatitis A, D and E, meaning the findings are largely driven by literature on hepatitis B and C. Some relevant studies may have been missed if they were not included in the systematic reviews. The review also encountered substantial heterogeneity across study populations and regions. Although efforts were made to include all robust data, the inability to distinguish between acute, chronic or past hepatitis infections remains a limitation. Most studies identified cases based on seropositivity, which does not necessarily indicate active infection or liver dysfunction. As such, the reported prevalence reflects serological diagnoses rather than confirmed clinical cases. Furthermore, the included populations, such as pregnant women, patients with HIV, blood donors and other high-risk groups are more likely to undergo screening, which may influence the prevalence estimates reported. For hepatitis D, prevalence estimates are further complicated by limited access to HDV serology and HCV RNA testing, which are often restricted to the research setting. Current HDV serological assays may also fail to detect genotypes 5&#8211;8, which are prevalent in SSA, potentially leading to underestimation of the true disease burden. Finally, selection and publication biases common in umbrella reviews are likely present, and caution is advised when interpreting the results.</p></sec></sec><sec sec-type="conclusions" id="s5"><title>Conclusion</title><p>This is the first umbrella review evaluating the prevalence of viral hepatitis in the general population within SSA. The result from this study helps better understand the burden of viral hepatitis. Our findings should be interpreted with caution, considering that the reported prevalence was based on seropositive tests, and the impact of other factors on the estimates could not be ascertained. The findings from this umbrella review provide researchers and public health experts with an overarching picture of the burden of viral hepatitis in SSA.</p></sec><sec sec-type="supplementary-material" id="s6"><title>Supplementary material</title><supplementary-material id="SP1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/bmjopen-2025-101029</object-id><label>online supplemental file 1</label><media xlink:href="bmjopen-15-9-s001.docx" id="d67e1559" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>The authors thank Vivek Dhawan and Sweety Wargaonkar of Novartis Healthcare Pvt. Ltd., Hyderabad, India, for providing editorial support, which was funded by Novartis Pharma AG, Basel, Switzerland, in accordance with Good Publication Practice (GPP) guidelines (<ext-link xlink:href="https://www.ismpp.org/gpp-2022" ext-link-type="uri">https://www.ismpp.org/gpp-2022</ext-link>).</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The study was sponsored by Novartis Pharma AG. This work was part of JSS&#8217;s master&#8217;s thesis supervised by OAO and KRC at Novartis Pharma AG, Basel, Switzerland and Andrea Burden at the Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.</p></fn><fn fn-type="other"><p>Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<ext-link xlink:href="https://doi.org/10.1136/bmjopen-2025-101029" ext-link-type="uri">https://doi.org/10.1136/bmjopen-2025-101029</ext-link>).</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Ethics approval:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Map disclaimer:</bold> The depiction of boundaries on this map does not imply the expression of any opinion whatsoever on the part of BMJ (or any member of its group) concerning the legal status of any country, territory, jurisdiction or area or of its authorities. This map is provided without any warranty of any kind, either express or implied.</p></fn><fn fn-type="other"><p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devarbhavi</surname><given-names>H</given-names></name><name name-style="western"><surname>Asrani</surname><given-names>SK</given-names></name><name name-style="western"><surname>Arab</surname><given-names>JP</given-names></name><etal>et al</etal></person-group><article-title>Global burden of liver disease: 2023 update</article-title><source>J Hepatol</source><year>2023</year><volume>79</volume><fpage>516</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2023.03.017</pub-id><pub-id pub-id-type="pmid">36990226</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sonderup</surname><given-names>MW</given-names></name><name name-style="western"><surname>Afihene</surname><given-names>M</given-names></name><name name-style="western"><surname>Ally</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030</article-title><source>Lancet Gastroenterol Hepatol</source><year>2017</year><volume>2</volume><fpage>910</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(17)30249-2</pub-id><pub-id pub-id-type="pmid">29132760</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="other"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Global hepatitis report 2017</article-title><year>2017</year></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parkin</surname><given-names>DM</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Estimating the world cancer burden: Globocan 2000</article-title><source><italic toggle="yes">Int J Cancer</italic></source><year>2001</year><volume>94</volume><fpage>153</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1002/ijc.1440</pub-id><pub-id pub-id-type="pmid">11668491</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Hepatitis B</source><year>2024</year><comment>Available</comment><ext-link xlink:href="https://www.who.int/news-room/fact-sheets/detail/hepatitis-b" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/hepatitis-b</ext-link></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Hepatitis C</source><year>2024</year><comment>Available</comment><ext-link xlink:href="https://www.who.int/news-room/fact-sheets/detail/hepatitis-c" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/hepatitis-c</ext-link></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Hepatitis D</source><year>2024</year><comment>Available</comment><ext-link xlink:href="https://www.who.int/news-room/fact-sheets/detail/hepatitis-d" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/hepatitis-d</ext-link></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizzetto</surname><given-names>M</given-names></name><name name-style="western"><surname>Verme</surname><given-names>G</given-names></name><name name-style="western"><surname>Recchia</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment</article-title><source>Ann Intern Med</source><year>1983</year><volume>98</volume><fpage>437</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-98-4-437</pub-id><pub-id pub-id-type="pmid">6340574</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizzetto</surname><given-names>M</given-names></name><name name-style="western"><surname>Canese</surname><given-names>MG</given-names></name><name name-style="western"><surname>Aric&#242;</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers</article-title><source>Gut</source><year>1977</year><volume>18</volume><fpage>997</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1136/gut.18.12.997</pub-id><pub-id pub-id-type="pmid">75123</pub-id><pub-id pub-id-type="pmcid">PMC1411847</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mokdad</surname><given-names>AA</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>AD</given-names></name><name name-style="western"><surname>Shahraz</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis</article-title><source>BMC Med</source><year>2014</year><volume>12</volume><fpage>145</fpage><pub-id pub-id-type="doi">10.1186/s12916-014-0145-y</pub-id><pub-id pub-id-type="pmid">25242656</pub-id><pub-id pub-id-type="pmcid">PMC4169640</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sepanlou</surname><given-names>SG</given-names></name><name name-style="western"><surname>Safiri</surname><given-names>S</given-names></name><name name-style="western"><surname>Bisignano</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990&#8211;2017: a systematic analysis for the Global Burden of Disease Study 2017</article-title><source>Lancet Gastroenterol Hepatol</source><year>2020</year><volume>5</volume><fpage>245</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(19)30349-8</pub-id><pub-id pub-id-type="pmid">31981519</pub-id><pub-id pub-id-type="pmcid">PMC7026710</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spearman</surname><given-names>CW</given-names></name><name name-style="western"><surname>Afihene</surname><given-names>M</given-names></name><name name-style="western"><surname>Ally</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets</article-title><source>Lancet Gastroenterol Hepatol</source><year>2017</year><volume>2</volume><fpage>900</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(17)30295-9</pub-id><pub-id pub-id-type="pmid">29132759</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gower</surname><given-names>E</given-names></name><name name-style="western"><surname>Estes</surname><given-names>C</given-names></name><name name-style="western"><surname>Blach</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Global epidemiology and genotype distribution of the hepatitis C virus infection</article-title><source>J Hepatol</source><year>2014</year><volume>61</volume><fpage>S45</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2014.07.027</pub-id><pub-id pub-id-type="pmid">25086286</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ioannidis</surname><given-names>JPA</given-names></name></person-group><article-title>Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses</article-title><source>CMAJ</source><year>2009</year><volume>181</volume><fpage>488</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1503/cmaj.081086</pub-id><pub-id pub-id-type="pmid">19654195</pub-id><pub-id pub-id-type="pmcid">PMC2761440</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belbasis</surname><given-names>L</given-names></name><name name-style="western"><surname>Bellou</surname><given-names>V</given-names></name><name name-style="western"><surname>Ioannidis</surname><given-names>JPA</given-names></name></person-group><article-title>Conducting umbrella reviews</article-title><source><italic toggle="yes">BMJ Med</italic></source><year>2022</year><volume>1</volume><elocation-id>e000071</elocation-id><pub-id pub-id-type="doi">10.1136/bmjmed-2021-000071</pub-id><pub-id pub-id-type="pmcid">PMC9951359</pub-id><pub-id pub-id-type="pmid">36936579</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>UN Statistics Division</collab></person-group><source>Standard country or area codes for statistical use (M49)</source><year>2024</year><comment>Available</comment><ext-link xlink:href="https://unstats.un.org/unsd/methodology/m49/#geo-regions" ext-link-type="uri">https://unstats.un.org/unsd/methodology/m49/#geo-regions</ext-link></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aromataris</surname><given-names>E</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>R</given-names></name><name name-style="western"><surname>Godfrey</surname><given-names>CM</given-names></name><etal>et al</etal></person-group><article-title>Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach</article-title><source>JBI Evidence Implementation</source><year>2015</year><volume>13</volume><fpage>132</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1097/XEB.0000000000000055</pub-id><pub-id pub-id-type="pmid">26360830</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan-Kadle</surname><given-names>MA</given-names></name><name name-style="western"><surname>Osman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Ogurtsov</surname><given-names>PP</given-names></name></person-group><article-title>Epidemiology of viral hepatitis in Somalia: Systematic review and meta-analysis study</article-title><source>World J Gastroenterol</source><year>2018</year><volume>24</volume><fpage>3927</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.3748/wjg.v24.i34.3927</pub-id><pub-id pub-id-type="pmid">30228786</pub-id><pub-id pub-id-type="pmcid">PMC6141335</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bigna</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Amougou</surname><given-names>MA</given-names></name><name name-style="western"><surname>Asangbeh</surname><given-names>SL</given-names></name><etal>et al</etal></person-group><article-title>Seroprevalence of hepatitis B virus infection in Cameroon: a systematic review and meta-analysis</article-title><source>BMJ Open</source><year>2017</year><volume>7</volume><elocation-id>e015298</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2016-015298</pub-id><pub-id pub-id-type="pmcid">PMC5734365</pub-id><pub-id pub-id-type="pmid">28667212</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badawi</surname><given-names>MM</given-names></name><name name-style="western"><surname>Atif</surname><given-names>MS</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>YY</given-names></name></person-group><article-title>Systematic review and meta-analysis of HIV, HBV and HCV infection prevalence in Sudan</article-title><source>Virol J</source><year>2018</year><volume>15</volume><elocation-id>148</elocation-id><pub-id pub-id-type="doi">10.1186/s12985-018-1060-1</pub-id><pub-id pub-id-type="pmid">30253805</pub-id><pub-id pub-id-type="pmcid">PMC6157049</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belyhun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Maier</surname><given-names>M</given-names></name><name name-style="western"><surname>Mulu</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Hepatitis viruses in Ethiopia: a systematic review and meta-analysis</article-title><source>BMC Infect Dis</source><year>2016</year><volume>16</volume><elocation-id>761</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-016-2090-1</pub-id><pub-id pub-id-type="pmid">27993129</pub-id><pub-id pub-id-type="pmcid">PMC5168848</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kafeero</surname><given-names>HM</given-names></name><name name-style="western"><surname>Ndagire</surname><given-names>D</given-names></name><name name-style="western"><surname>Ocama</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Prevalence and predictors of hepatitis B virus (HBV) infection in east Africa: evidence from a systematic review and meta-analysis of epidemiological studies published from 2005 to 2020</article-title><source>Arch Public Health</source><year>2021</year><volume>79</volume><elocation-id>167</elocation-id><pub-id pub-id-type="doi">10.1186/s13690-021-00686-1</pub-id><pub-id pub-id-type="pmid">34537079</pub-id><pub-id pub-id-type="pmcid">PMC8449462</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makokha</surname><given-names>GN</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>CN</given-names></name><etal>et al</etal></person-group><article-title>The burden of hepatitis B virus infection in Kenya: a systematic review and meta-analysis</article-title><source>Front Public Health</source><year>2023</year><volume>11</volume><elocation-id>986020</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2023.986020</pub-id><pub-id pub-id-type="pmid">36778557</pub-id><pub-id pub-id-type="pmcid">PMC9909240</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stockdale</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Mitambo</surname><given-names>C</given-names></name><name name-style="western"><surname>Everett</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>Epidemiology of hepatitis B, C and D in Malawi: systematic review</article-title><source>BMC Infect Dis</source><year>2018</year><volume>18</volume><elocation-id>516</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-018-3428-7</pub-id><pub-id pub-id-type="pmid">30314448</pub-id><pub-id pub-id-type="pmcid">PMC6186098</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yazie</surname><given-names>TD</given-names></name><name name-style="western"><surname>Tebeje</surname><given-names>MG</given-names></name></person-group><article-title>An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia</article-title><source>BMC Infect Dis</source><year>2019</year><volume>19</volume><elocation-id>917</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-019-4486-1</pub-id><pub-id pub-id-type="pmid">31664923</pub-id><pub-id pub-id-type="pmcid">PMC6820955</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abesig</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Prevalence of viral hepatitis B in Ghana between 2015 and 2019: a systematic review and meta-analysis</article-title><source>PLoS One</source><year>2020</year><volume>15</volume><elocation-id>e0234348</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0234348</pub-id><pub-id pub-id-type="pmid">32530945</pub-id><pub-id pub-id-type="pmcid">PMC7292378</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ajuwon</surname><given-names>BI</given-names></name><name name-style="western"><surname>Yujuico</surname><given-names>I</given-names></name><name name-style="western"><surname>Roper</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Hepatitis B virus infection in Nigeria: a systematic review and meta-analysis of data published between 2010 and 2019</article-title><source>BMC Infect Dis</source><year>2021</year><volume>21</volume><elocation-id>1120</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-021-06800-6</pub-id><pub-id pub-id-type="pmid">34717586</pub-id><pub-id pub-id-type="pmcid">PMC8556927</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lingani</surname><given-names>M</given-names></name><name name-style="western"><surname>Akita</surname><given-names>T</given-names></name><name name-style="western"><surname>Ouoba</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>High prevalence of hepatitis B infections in Burkina Faso (1996-2017): a systematic review with meta-analysis of epidemiological studies</article-title><source>BMC Public Health</source><year>2018</year><volume>18</volume><elocation-id>551</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-018-5432-7</pub-id><pub-id pub-id-type="pmid">29699534</pub-id><pub-id pub-id-type="pmcid">PMC5921387</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musa</surname><given-names>BM</given-names></name><name name-style="western"><surname>Bussell</surname><given-names>S</given-names></name><name name-style="western"><surname>Borodo</surname><given-names>MM</given-names></name><etal>et al</etal></person-group><article-title>Prevalence of hepatitis B virus infection in Nigeria, 2000-2013: a systematic review and meta-analysis</article-title><source>Niger J Clin Pract</source><year>2015</year><volume>18</volume><fpage>163</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.4103/1119-3077.151035</pub-id><pub-id pub-id-type="pmid">25665986</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ofori-Asenso</surname><given-names>R</given-names></name><name name-style="western"><surname>Agyeman</surname><given-names>AA</given-names></name></person-group><article-title>Hepatitis B in Ghana: a systematic review &amp; meta-analysis of prevalence studies (1995-2015)</article-title><source>BMC Infect Dis</source><year>2016</year><volume>16</volume><elocation-id>130</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-016-1467-5</pub-id><pub-id pub-id-type="pmid">26987556</pub-id><pub-id pub-id-type="pmcid">PMC4797341</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bigna</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Amougou</surname><given-names>MA</given-names></name><name name-style="western"><surname>Asangbeh</surname><given-names>SL</given-names></name><etal>et al</etal></person-group><article-title>Seroprevalence of hepatitis C virus infection in Cameroon: a systematic review and meta-analysis</article-title><source>BMJ Open</source><year>2017</year><volume>7</volume><elocation-id>e015748</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2016-015748</pub-id><pub-id pub-id-type="pmcid">PMC5724202</pub-id><pub-id pub-id-type="pmid">28851778</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohd Hanafiah</surname><given-names>K</given-names></name><name name-style="western"><surname>Groeger</surname><given-names>J</given-names></name><name name-style="western"><surname>Flaxman</surname><given-names>AD</given-names></name><etal>et al</etal></person-group><article-title>Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence</article-title><source>Hepatology</source><year>2013</year><volume>57</volume><fpage>1333</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1002/hep.26141</pub-id><pub-id pub-id-type="pmid">23172780</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mora</surname><given-names>N</given-names></name><name name-style="western"><surname>Adams</surname><given-names>WH</given-names></name><name name-style="western"><surname>Kliethermes</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>A synthesis of hepatitis C prevalence estimates in sub-Saharan Africa: 2000-2013</article-title><source>BMC Infect Dis</source><year>2016</year><volume>16</volume><elocation-id>283</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-016-1584-1</pub-id><pub-id pub-id-type="pmid">27296465</pub-id><pub-id pub-id-type="pmcid">PMC4906983</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muzembo</surname><given-names>BA</given-names></name><name name-style="western"><surname>Akita</surname><given-names>T</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Systematic review and meta-analysis of hepatitis C virus infection in the Democratic Republic of Congo</article-title><source>Public Health (Fairfax)</source><year>2016</year><volume>139</volume><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.puhe.2016.06.017</pub-id><pub-id pub-id-type="pmid">27450441</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>VB</given-names></name><name name-style="western"><surname>Johari</surname><given-names>N</given-names></name><name name-style="western"><surname>du Cros</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis</article-title><source>Lancet Infect Dis</source><year>2015</year><volume>15</volume><fpage>819</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)00006-7</pub-id><pub-id pub-id-type="pmid">25957078</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaabna</surname><given-names>K</given-names></name><name name-style="western"><surname>Kouyoumjian</surname><given-names>SP</given-names></name><name name-style="western"><surname>Abu-Raddad</surname><given-names>LJ</given-names></name></person-group><article-title>Hepatitis C virus epidemiology in Djibouti, Somalia, Sudan, and Yemen: systematic review and meta-analysis</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><elocation-id>e0149966</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0149966</pub-id><pub-id pub-id-type="pmid">26900839</pub-id><pub-id pub-id-type="pmcid">PMC4764686</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deress</surname><given-names>T</given-names></name><name name-style="western"><surname>Million</surname><given-names>Y</given-names></name><name name-style="western"><surname>Belachew</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Seroprevalence of hepatitis C viral infection in Ethiopia: a systematic review and meta-analysis</article-title><source>ScientificWorldJournal</source><year>2021</year><volume>2021</volume><elocation-id>8873389</elocation-id><pub-id pub-id-type="doi">10.1155/2021/8873389</pub-id><pub-id pub-id-type="pmid">33897305</pub-id><pub-id pub-id-type="pmcid">PMC8052182</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stockdale</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Chaponda</surname><given-names>M</given-names></name><name name-style="western"><surname>Beloukas</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis</article-title><source>Lancet Glob Health</source><year>2017</year><volume>5</volume><fpage>e992</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(17)30298-X</pub-id><pub-id pub-id-type="pmid">28911765</pub-id><pub-id pub-id-type="pmcid">PMC5599428</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jadice Mandimba</surname><given-names>WPT</given-names></name><name name-style="western"><surname>Wangou</surname><given-names>MM</given-names></name><name name-style="western"><surname>Bataliack</surname><given-names>SM</given-names></name><etal>et al</etal></person-group><source>Hepatitis can&#8217;t wait [fact sheet]</source><publisher-loc>World Health Organization</publisher-loc><year>2023</year></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bile</surname><given-names>AS</given-names></name><name name-style="western"><surname>Ali-Salad</surname><given-names>MA</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>AJ</given-names></name><etal>et al</etal></person-group><article-title>Assessing vaccination delivery strategies for zero-dose and under-immunized children in the fragile context of Somalia</article-title><source>Vaccines (Basel)</source><year>2024</year><volume>12</volume><elocation-id>154</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12020154</pub-id><pub-id pub-id-type="pmid">38400137</pub-id><pub-id pub-id-type="pmcid">PMC10892412</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schweitzer</surname><given-names>A</given-names></name><name name-style="western"><surname>Horn</surname><given-names>J</given-names></name><name name-style="western"><surname>Mikolajczyk</surname><given-names>RT</given-names></name><etal>et al</etal></person-group><article-title>Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013</article-title><source>Lancet</source><year>2015</year><volume>386</volume><fpage>1546</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)61412-X</pub-id><pub-id pub-id-type="pmid">26231459</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hadler</surname><given-names>SC</given-names></name><name name-style="western"><surname>Judson</surname><given-names>FN</given-names></name><name name-style="western"><surname>O&#8217;Malley</surname><given-names>PM</given-names></name><etal>et al</etal></person-group><article-title>Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection</article-title><source>J Infect Dis</source><year>1991</year><volume>163</volume><fpage>454</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/infdis/163.3.454</pub-id><pub-id pub-id-type="pmid">1825315</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edmunds</surname><given-names>W</given-names></name><name name-style="western"><surname>Medley</surname><given-names>G</given-names></name><name name-style="western"><surname>Nokes</surname><given-names>D</given-names></name></person-group><article-title>The influence of age on the development of the hepatitis B carrier state</article-title><source>Proc R Soc Lond B</source><year>1993</year><volume>253</volume><fpage>197</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1098/rspb.1993.0102</pub-id><pub-id pub-id-type="pmid">8397416</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cutts</surname><given-names>FT</given-names></name><name name-style="western"><surname>Izurieta</surname><given-names>HS</given-names></name><name name-style="western"><surname>Rhoda</surname><given-names>DA</given-names></name></person-group><article-title>Measuring coverage in MNCH: design, implementation, and interpretation challenges associated with tracking vaccination coverage using household surveys</article-title><source>PLoS Med</source><year>2013</year><volume>10</volume><elocation-id>e1001404</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1001404</pub-id><pub-id pub-id-type="pmid">23667334</pub-id><pub-id pub-id-type="pmcid">PMC3646208</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rainey</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>M</given-names></name><name name-style="western"><surname>Ryman</surname><given-names>TK</given-names></name><etal>et al</etal></person-group><article-title>Reasons related to non-vaccination and under-vaccination of children in low and middle income countries: findings from a systematic review of the published literature, 1999-2009</article-title><source>Vaccine (Auckl)</source><year>2011</year><volume>29</volume><fpage>8215</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.08.096</pub-id><pub-id pub-id-type="pmid">21893149</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Africa Region (World Health Organization)</collab></person-group><source>91 million Africans infected with hepatitis B or C</source><year>2022</year><comment>Available</comment><ext-link xlink:href="https://www.afro.who.int/news/91-million-africans-infected-hepatitis-b-or-c" ext-link-type="uri">https://www.afro.who.int/news/91-million-africans-infected-hepatitis-b-or-c</ext-link></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salari</surname><given-names>N</given-names></name><name name-style="western"><surname>Kazeminia</surname><given-names>M</given-names></name><name name-style="western"><surname>Hemati</surname><given-names>N</given-names></name><etal>et al</etal></person-group><article-title>Global prevalence of hepatitis C in general population: a systematic review and meta-analysis</article-title><source>Travel Med Infect Dis</source><year>2022</year><volume>46</volume><pub-id pub-id-type="doi">10.1016/j.tmaid.2022.102255</pub-id><pub-id pub-id-type="pmid">35007756</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>K</given-names></name><name name-style="western"><surname>Muir</surname><given-names>AJ</given-names></name><name name-style="western"><surname>McHutchison</surname><given-names>JG</given-names></name></person-group><article-title>Diagnosis and treatment of chronic hepatitis C infection</article-title><source>BMJ</source><year>2006</year><volume>332</volume><fpage>1013</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1136/bmj.332.7548.1013</pub-id><pub-id pub-id-type="pmid">16644828</pub-id><pub-id pub-id-type="pmcid">PMC1450048</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serranti</surname><given-names>D</given-names></name><name name-style="western"><surname>Indolfi</surname><given-names>G</given-names></name><name name-style="western"><surname>Nebbia</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>Transient hypothyroidism and autoimmune thyroiditis in children with chronic hepatitis C treated with pegylated-interferon-&#945;-2b and ribavirin</article-title><source>Pediatr Infect Dis J</source><year>2018</year><volume>37</volume><fpage>287</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000001791</pub-id><pub-id pub-id-type="pmid">28953189</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gebreselassie</surname><given-names>L</given-names></name></person-group><article-title>Prevalence of specific markers of viral hepatitis A and B among an Ethiopian population</article-title><source>Bull World Health Organ</source><year>1983</year><volume>61</volume><fpage>991</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">6325033</pub-id><pub-id pub-id-type="pmcid">PMC2536248</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsega</surname><given-names>E</given-names></name><name name-style="western"><surname>Mengesha</surname><given-names>B</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>BG</given-names></name><etal>et al</etal></person-group><article-title>Hepatitis A, B, and delta infection in Ethiopia: a serologic survey with demographic data</article-title><source>Am J Epidemiol</source><year>1986</year><volume>123</volume><fpage>344</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a114243</pub-id><pub-id pub-id-type="pmid">3511678</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsega</surname><given-names>E</given-names></name><name name-style="western"><surname>Nordenfelt</surname><given-names>E</given-names></name><name name-style="western"><surname>Mengesha</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Age-specific prevalence of hepatitis A virus antibody in Ethiopian children</article-title><source>Scand J Infect Dis</source><year>1990</year><volume>22</volume><fpage>145</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.3109/00365549009037894</pub-id><pub-id pub-id-type="pmid">2356438</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobsen</surname><given-names>KH</given-names></name><name name-style="western"><surname>Koopman</surname><given-names>JS</given-names></name></person-group><article-title>Declining hepatitis A seroprevalence: a global review and analysis</article-title><source>Epidemiol Infect</source><year>2004</year><volume>132</volume><fpage>1005</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1017/S0950268804002857</pub-id><pub-id pub-id-type="pmid">15635957</pub-id><pub-id pub-id-type="pmcid">PMC2870191</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wasley</surname><given-names>A</given-names></name><name name-style="western"><surname>Fiore</surname><given-names>A</given-names></name><name name-style="western"><surname>Bell</surname><given-names>BP</given-names></name></person-group><article-title>Hepatitis A in the era of vaccination</article-title><source>Epidemiol Rev</source><year>2006</year><volume>28</volume><fpage>101</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1093/epirev/mxj012</pub-id><pub-id pub-id-type="pmid">16775039</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gust</surname><given-names>ID</given-names></name></person-group><article-title>Epidemiological patterns of hepatitis A in different parts of the world</article-title><source>Vaccine (Auckl)</source><year>1992</year><volume>10 Suppl 1</volume><fpage>S56</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/0264-410x(92)90544-t</pub-id><pub-id pub-id-type="pmid">1335660</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karim</surname><given-names>SA</given-names></name><name name-style="western"><surname>Coutsoudis</surname><given-names>A</given-names></name></person-group><article-title>Sero-epidemiology ofhepatitis A in black South African children</article-title><source>South Afr Med J</source><year>1993</year><volume>83</volume><fpage>746</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">8191332</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="other"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Hepatitis A vaccines: WHO position paper, October 2022. Weekly Epidemiological Record. Guidline ed</article-title><year>2022</year></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizzetto</surname><given-names>M</given-names></name><name name-style="western"><surname>Hamid</surname><given-names>S</given-names></name><name name-style="western"><surname>Negro</surname><given-names>F</given-names></name></person-group><article-title>The changing context of hepatitis D</article-title><source>J Hepatol</source><year>2021</year><volume>74</volume><fpage>1200</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.01.014</pub-id><pub-id pub-id-type="pmid">33484770</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizzetto</surname><given-names>M</given-names></name></person-group><article-title>Hepatitis D virus: introduction and epidemiology</article-title><source>Cold Spring Harb Perspect Med</source><year>2015</year><volume>5</volume><elocation-id>a021576</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a021576</pub-id><pub-id pub-id-type="pmid">26134842</pub-id><pub-id pub-id-type="pmcid">PMC4484953</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>The global epidemiology of hepatitis E virus infection: a systematic review and meta-analysis</article-title><source>Liver Int</source><year>2020</year><volume>40</volume><fpage>1516</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1111/liv.14468</pub-id><pub-id pub-id-type="pmid">32281721</pub-id><pub-id pub-id-type="pmcid">PMC7384095</pub-id></element-citation></ref></ref-list><sec sec-type="data-availability"><title>Data availability statement</title><p>All data relevant to the study are included in the manuscript or uploaded as supplementary information. The data generated and/or analyzed during the current study consist of data extracted from previously published studies, which are adequately referenced in the manuscript or supplementary information.</p></sec></back><sub-article id="sub-article1" article-type="aggregated-review-documents"><front-stub><title-group><article-title>Review Process File</article-title></title-group><pub-date pub-type="epub"><day>02</day><month>09</month><year>2025</year></pub-date></front-stub><body><fig id="d67e3016" position="anchor" orientation="portrait"><media xlink:href="bmjopen-2025-101029.reviewer_comments.pdf" position="float" orientation="portrait"/></fig></body></sub-article></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>